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1. INTRODUCTION {#dom13278-sec-0001}
===============

Severe hypoglycaemia is a serious and potentially life‐threatening complication of insulin therapy.[1](#dom13278-bib-0001){ref-type="ref"}, [2](#dom13278-bib-0002){ref-type="ref"} Patients with type 1 diabetes (T1D) experience \~2 symptomatic hypoglycaemic events (HEs)/week and 1 severe HE/year.[2](#dom13278-bib-0002){ref-type="ref"}, [3](#dom13278-bib-0003){ref-type="ref"} Fear of hypoglycaemia is a major barrier to the achievement of glycaemic targets in people with T1D.[1](#dom13278-bib-0001){ref-type="ref"}, [4](#dom13278-bib-0004){ref-type="ref"} Carbohydrate ingestion may not be possible in severe hypoglycaemia where the person may be unconscious or having a seizure.[5](#dom13278-bib-0005){ref-type="ref"} In this scenario, caregivers can either inject glucagon or wait for professional help. The currently available glucagon kits require reconstitution prior to administration.[1](#dom13278-bib-0001){ref-type="ref"}, [6](#dom13278-bib-0006){ref-type="ref"} Nasal glucagon (NG), a needle‐free, single‐use, compact, portable, drug‐device combination consisting of 3 mg dry glucagon powder that does not require reconstitution, is currently under development as a rescue medication for severe hypoglycaemia.[1](#dom13278-bib-0001){ref-type="ref"} NG (3 mg) produced a rapid increase in blood glucose (BG) levels and was non‐inferior to intramuscular glucagon (1 mg) in a previous study in adults with insulin‐induced hypoglycaemia.[5](#dom13278-bib-0005){ref-type="ref"} The aim of the present study was to evaluate the real‐world effectiveness, tolerability and ease of use of NG (3 mg nasal glucagon; Eli Lilly and Company) in the treatment of moderate and severe HEs in adults with T1D.

2. MATERIALS AND METHODS {#dom13278-sec-0002}
========================

This was a prospective, single‐arm, real‐world study. A severe HE was defined as an event during which the person with diabetes is clinically incapacitated and requires third‐party assistance. A moderate HE was defined as an event during which the person with diabetes shows signs and symptoms of neuroglycopaenia with BG ≤3.3 mmol/L (60 mg/dL) at or near the time of treatment. The study was conducted at 9 centres from May 2014 to July 2015 according to the principles of Good Clinical Practice and was registered in <http://clinicaltrials.gov> (NCT02171130).

Adults (aged 18‐75 years) with T1D of \>1‐year duration and a body mass index ≥18.5 and ≤35.0 kg/m^2^ were included; each patient was required to have a caregiver to administer NG as needed. Hypoglycaemia awareness at baseline was evaluated using the Clarke Hypoglycaemia Awareness questionnaire (Appendix [S1](#dom13278-supitem-0001){ref-type="supplementary-material"}).[7](#dom13278-bib-0007){ref-type="ref"} Patients and caregivers were trained to use NG. Caregivers were instructed to administer a single NG dose when the patient experienced a moderate/severe HE and to measure capillary BG levels at the time of dosing and \~15, 30 and 45 minutes thereafter. Treatment response was defined as awakening (recovering consciousness/recovery from convulsions) and/or returning to normal status within 30 minutes of NG administration, as per caregivers\' assessment. Caregivers were required to seek emergency medical aid or use injectable glucagon if the patient did not respond within 30 minutes (or even earlier if needed). Caregivers were asked to complete a Hypoglycaemia Episode Questionnaire (Appendix [S2](#dom13278-supitem-0001){ref-type="supplementary-material"}) and a User‐Friendliness Assessment Questionnaire (Appendix [S3](#dom13278-supitem-0001){ref-type="supplementary-material"}). Patients had to complete a Nasal Score Questionnaire (Appendix [S4](#dom13278-supitem-0001){ref-type="supplementary-material"}) after recovery from the HE.

The primary outcome was the proportion of patients awakening or returning to normal status within 30 minutes of NG administration. Because some patients experienced \>1 HE, the proportion of events in which patients awakened or returned to normal status within 30 minutes was also assessed. Other outcome measures included change in BG levels, tolerability, and ease of use of NG based on caregivers\' assessment.

The efficacy analysis population included eligible patients who received ≥1 NG dose with evaluable response information; HEs in which patients required oral carbohydrates/injectable glucagon/professional medical assistance within 30 minutes and before clinical response, were excluded from the efficacy analysis population. The main safety analysis population comprised eligible patients who experienced ≥1 HE and received ≥1 NG dose. A total of 21 patients were considered ineligible (16 because of a clinical trial material issue resulting in potential under‐dose, 5 because of site termination). SAS 9.3 was used to produce descriptive statistics.

3. RESULTS {#dom13278-sec-0003}
==========

Patient disposition and baseline characteristics are shown in Figure [S1](#dom13278-supitem-0001){ref-type="supplementary-material"} and Table [S1](#dom13278-supitem-0001){ref-type="supplementary-material"}, respectively. Out of 129 patients enrolled, 101 completed the study; 87 received ≥1 NG dose. The main safety analysis population included 74 patients (179 events); the efficacy analysis population included 69 patients (157 events).

3.1. Efficacy results {#dom13278-sec-0004}
---------------------

A total of 66 patients (95.7%) in the efficacy analysis population awakened or achieved normality within 30 minutes after NG administration in at least 1 evaluable event whereas 64 patients (92.8%) awakened or achieved normality in all evaluable events (Table [1](#dom13278-tbl-0001){ref-type="table-wrap"}).

###### 

Return to normal status or awakening within 30 minutes after nasal glucagon administration in the efficacy analysis population

  Patients who experienced ≥1 moderate/severe HE (number of patients, *N* = 69)                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  Number of patients who awakened or returned to normal status within 30 min *in at least 1 evaluable event* (%)                                                      66 (95.7)
  Number of patients who awakened or returned to normal status within 30 min *in all evaluable events* (%)                                                            64 (92.8)
  **Moderate/severe HEs (number of events, *N* = 157)**                                                                                          
  Number of HEs in which patients awakened or returned to normal status within 30 min (%)                                                         151 (96.2)[a](#dom13278-note-0003){ref-type="fn"}
  **Severe HEs (*n* = 12)**                                                                                                                      
  Time to awaken from severe event where patient was unconscious or had convulsions (*n* = 10)[b](#dom13278-note-0004){ref-type="fn"}, *n* (%)   
  \<5 min                                                                                                                                                             1 (10.0)
  5 to \<10 min                                                                                                                                                       6 (60.0)
  10 to \<15 min                                                                                                                                                      3 (30.0)
  Time to return to normal status from severe event where patient was conscious (*n* = 2)[c](#dom13278-note-0005){ref-type="fn"}, *n* (%)        
  5 to \<10 min                                                                                                                                                        2 (100)
  **Moderate HEs (*n* = 145)**                                                                                                                   
  Time to return to normal status[d](#dom13278-note-0006){ref-type="fn"}, *n* (%)                                                                
  \<5 min                                                                                                                                                             27 (18.6)
  5 to \<10 min                                                                                                                                                       43 (29.7)
  10 to \<15 min                                                                                                                                                      33 (22.8)
  15 to \<20 min                                                                                                                                                      23 (15.9)
  20 to \<25 min                                                                                                                                                       7 (4.8)
  25 to \<30 min                                                                                                                                                       6 (4.1)
  30 to \<45 min                                                                                                                                                       5 (3.4)
  Other                                                                                                                                            1[e](#dom13278-note-0007){ref-type="fn"} (0.7)

Abbreviations: HE, hypoglycaemic event; NG, nasal glucagon.

Details regarding the 6 HEs in which patients did not return to normal status within 30 min are presented in Table [S2](#dom13278-supitem-0001){ref-type="supplementary-material"}.

Percentages based on the total number of events where "Time to awaken from severe event where patient was unconscious or had convulsions" was reported (*n* = 10).

Percentages based on the total number of events where "Time to return to normal status from severe event where patient was conscious" was reported (*n* = 2).

Percentages based on the total number of moderate events (*n* = 145).

In this HE, the patient reported persistent headache, which prevented the patient from returning to normal status.

Out of 157 evaluable HEs (145 moderate; 12 severe), 151 events (96.2%) resolved within 30 minutes after NG administration. Mean BG levels increased progressively from 2.7 mmol/L (47.9 mg/dL) at the time of NG administration to 4.7 mmol/L (84.4 mg/dL) after 15 minutes and continued to increase further (Figure [S2](#dom13278-supitem-0001){ref-type="supplementary-material"}).

Six moderate, symptomatic HEs (3.8%) did not resolve within 30 minutes of NG administration. In 4 of these events, patients\' BG levels were \>3.9 mmol/L (70 mg/dL) within 30 minutes; however, they did not report return to normality because of headache and/or nasal irritation. In 2 events, BG levels increased by ≥1.1 mmol/L (20 mg/dL) and patients returned to normality between 30 and 45 minutes later (Table [S2](#dom13278-supitem-0001){ref-type="supplementary-material"}).

Seven patients in the efficacy analysis population reported 12 severe HEs, with BG levels ranging from 1.6 to 3.3 mmol/L (29 to 60 mg/dL) at the time of NG administration. In all severe HEs, including those in patients who were unconscious or had convulsions, patients awakened or returned to normality within 15 minutes of NG administration (Table [S3](#dom13278-supitem-0001){ref-type="supplementary-material"}).

There were 7 events (including 2 severe events) in 6 patients in whom oral carbohydrates were used before treatment success criteria were met (Table [S4](#dom13278-supitem-0001){ref-type="supplementary-material"}).

3.2. Safety results {#dom13278-sec-0005}
-------------------

Data on adverse events (AEs) were solicited through questionnaires. In the main safety analysis population, 87.8% patients experienced ≥1 AE. The most common AE was nasal irritation, reported by 82.4% of patients (Table [S5](#dom13278-supitem-0001){ref-type="supplementary-material"}); in more than half of these patients, it was short‐lasting and resolved within 1 hour. One patient withdrew from the study because of local nasal AEs. Most AEs were of low to moderate severity. No serious drug‐related AE was reported.

3.3. Ease of use and caregiver satisfaction {#dom13278-sec-0006}
-------------------------------------------

In most HEs, caregivers reported that it was easy to understand the kit instructions (91% events) and administer NG (80.5% events). Caregivers were able to administer NG within 30 seconds in 70.4% of events and within 1 minute in 92.7% of events. Overall, in 94.4% of HEs, caregivers were satisfied with NG use (Figure [1](#dom13278-fig-0001){ref-type="fig"}). Caregivers expressed willingness to carry NG (97.7% events) and agreed that NG was less intimidating than injectable glucagon (100% events).

![Ease of use of nasal glucagon (NG) and caregiver satisfaction in the main safety analysis population](DOM-20-1316-g001){#dom13278-fig-0001}

4. DISCUSSION {#dom13278-sec-0007}
=============

In the present real‐world study, we observed that 96.2% of HEs resolved within 30 minutes of NG administration. A previous randomized study in adults with T1D showed that 3‐mg NG was non‐inferior to 1‐mg intramuscular glucagon in treating insulin‐induced hypoglycaemia in a hospital setting.[5](#dom13278-bib-0005){ref-type="ref"} Another study in young people with T1D found that NG and injectable glucagon demonstrated similar glycaemic responses.[8](#dom13278-bib-0008){ref-type="ref"} The results of the present study, together with previous research, suggest that NG shows promise as an efficacious and effective medication for treatment of severe HEs in the real world.

This is the first clinical trial in which spontaneous, severe HEs were treated using NG. In all 12 severe HEs, patients awakened or returned to normality within 15 minutes of NG administration. No external professional emergency medical assistance was needed in any HE, indicating that caregivers could administer NG and manage the emergency situation themselves. Additionally, caregivers were able to administer NG within 30 seconds in 70.4% of events. These findings suggest that NG has the potential to empower caregivers to effectively manage severe HEs without delay, even in a stressful situation where patients are unconscious or having convulsions.

Hypoglycaemia has been associated with cardiac arrhythmias and increased risk of death in critically ill, hospitalized patients.[9](#dom13278-bib-0009){ref-type="ref"}, [10](#dom13278-bib-0010){ref-type="ref"} Recently, there has been increased awareness about the importance of clinically significant hypoglycaemia (identified by the International Hypoglycaemia Study Group as BG \<3.0 mmol/L \[54 mg/dL\]) with its associated risk of potential harm.[11](#dom13278-bib-0011){ref-type="ref"} Recent literature has also reported that hypoglycaemia with BG \<2.8 mmol/L (50 mg/dL) is associated with increased mortality; therefore, this cutoff could be an objective, measurable criterion by which to detect dangerous hypoglycaemia in a broader group of patients at risk of severe hypoglycaemia.[12](#dom13278-bib-0012){ref-type="ref"} In the present study, all patients who experienced moderate HEs had neuroglycopaenic symptoms and were at a risk of negative clinical outcomes; therefore, these moderate symptomatic events can be considered serious enough to represent surrogates for severe events.

Nausea and vomiting, well‐known side effects of glucagon, were reported in 23% and 9.5% of patients, respectively. Local AEs such as transient nasal irritation, were commonly reported with NG; many of these were of mild to moderate severity. Although nasal irritation was perceived as severe by 16.2% patients, this should be seen in the context of the potential benefit of NG as a life‐saving, rescue medication.

Caregivers reported that NG was easy to administer (80.5% events). They were able to administer the medication successfully within 30 seconds in the majority of cases (70.4% events) and were satisfied with NG use (94.4% events). Our findings are similar to those of a recent severe hypoglycaemia simulation study,[13](#dom13278-bib-0013){ref-type="ref"} which compared the user‐friendliness and success rate for administration of NG with injectable glucagon when administered to mannequins in a simulated severe hypoglycaemia situation. That study found that a higher percentage of people (caregivers and acquaintances) were able to administer NG as compared to injectable glucagon. Furthermore, the average time taken to administer NG was less than the time taken to administer injectable glucagon.[13](#dom13278-bib-0013){ref-type="ref"}

Injectable glucagon has been the treatment of choice for hypoglycaemia, and its efficacy is well established[1](#dom13278-bib-0001){ref-type="ref"}; however, injectable glucagon requires reconstitution and injection. In contrast, NG is needle‐free and ready‐to‐use, and a single 3‐mg dose can be used in both adult and paediatric patients independent of body weight.[14](#dom13278-bib-0014){ref-type="ref"} Our data showed that the 3‐mg NG drug‐device combination was not only efficacious but also showed effectiveness in a real‐world scenario. All patients with severe hypoglycaemia recovered within 15 minutes of NG administration, and all caregivers were able to use it successfully, confirming its effectiveness in the hands of the intended user.

A potential limitation of this pragmatic study is that it had a single arm; however, the protocol allowed the use of intramuscular glucagon, if needed. Additionally, there was a provision to call for emergency medical aid if the patient did not respond. This allowance to access emergency medical services in case of non‐response served as an alternative rescue option, which was not required in any HE. Because it has already been shown that NG is non‐inferior to injectable glucagon,[5](#dom13278-bib-0005){ref-type="ref"} the design of the present study was appropriate to investigate its effectiveness in the real world.

This phase III, real‐world study suggests that a single 3‐mg dose of NG may be a viable and effective option in treating severe hypoglycaemia in adults with T1D. Approximately 70% of caregivers were able to administer NG within 30 seconds; \>90% were able to administer it within 1 minute and no alternative external medical assistance was needed, confirming the effectiveness of NG in the hands of the final user. NG was found to be effective and reasonably well tolerated in adults with T1D.
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**Figure S1.** Patient disposition.
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**Table S2.** Summary of moderate hypoglycemic events in which patients did not return to normal status in 30 minutes after NG administration in the efficacy analysis population.

**Table S3.** Summary of severe hypoglycemic events in the efficacy analysis population.
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**Table S5.** Adverse events solicited through questionnaires in the main safety analysis population.

**Appendix S1.** Clarke hypoglycemia awareness survey.

**Appendix S2.** Hypoglycemia episode questionnaire.
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**Appendix S4.** Nasal score questionnaire.

###### 

Click here for additional data file.
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